Stock Traders Purchase High Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw unusually large options trading on Tuesday. Traders purchased 4,480 call options on the stock. This represents an increase of 124% compared to the average volume of 1,996 call options.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright increased their target price on Milestone Pharmaceuticals from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Monday. Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday. Finally, Wells Fargo & Company upped their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently modified their holdings of MIST. Propel Bio Management LLC raised its stake in Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after acquiring an additional 3,333,333 shares during the period. Orbimed Advisors LLC bought a new position in shares of Milestone Pharmaceuticals during the third quarter valued at approximately $6,444,000. Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after purchasing an additional 1,842,974 shares during the period. Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth approximately $2,000,000. Finally, Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth approximately $1,333,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Stock Performance

MIST stock opened at $2.15 on Thursday. The stock’s 50 day simple moving average is $2.19 and its 200 day simple moving average is $1.92. Milestone Pharmaceuticals has a 12-month low of $0.63 and a 12-month high of $3.06. The firm has a market cap of $183.12 million, a P/E ratio of -2.62 and a beta of 0.41. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.05. As a group, equities research analysts predict that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.